Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Monette

Psychiatry Gonzales, LA Medical Doctor

NPI 1699781591 CMS profile 696795

1112 E Ascension Complex Ave., Gonzales, LA 70737

Open in the dashboard

General payments

$3,894

217 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Monette of Gonzales, LA is reported in the CMS Open Payments database as having received $3,894 across 217 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $397 17
2024 General $520 24
2023 General $623 27
2022 General $611 34
2021 General $670 37
2020 General $385 26
2019 General $688 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Monette
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Brian Monette were reported at $397. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Brian Monette Psychiatry median Middle half National median
2019 $688 $184 $59–$605 $163
2020 $385 $119 $36–$372 $114
2021 $670 $143 $43–$576 $132
2022 $611 $153 $50–$590 $149
2023 $623 $170 $56–$651 $160
2024 $520 $179 $57–$673 $164
2025 $397 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ITI, Inc. $564 26 payments
  2. Sunovion Pharmaceuticals Inc. $485 24 payments
  3. Teva Pharmaceuticals USA, Inc. $484 27 payments
  4. AbbVie, Inc. $467 33 payments
  5. Otsuka America Pharmaceutical, Inc. $383 20 payments
  6. Alkermes, Inc. $327 14 payments
  7. Neurocrine Biosciences, Inc. $320 12 payments
  8. Janssen Pharmaceuticals, Inc $308 18 payments
  9. Allergan Inc. $266 28 payments
  10. Axsome Therapeutics, Inc. $92 3 payments
  11. Other $199 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,748 214 payments
  2. Education $146 3 payments
Products named General payments · program years 2019–2025
  1. CAPLYTA $550 25 payments
  2. LATUDA $485 24 payments
  3. VRAYLAR Neuroscience $467 33 payments
  4. REXULTI $351 18 payments
  5. LYBALVI $327 14 payments
  6. INGREZZA $320 12 payments
  7. ARISTADA Cns $303 13 payments
  8. ARISTADA Cns $303 13 payments
  9. UZEDY $266 9 payments
  10. VRAYLAR Neuroscience $266 28 payments
  11. Other $1,564 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

5,112

Median for Psychiatry: 574

Drug cost

$1,050,688

Median for Psychiatry: $27,624

Branded share of claims

21.5%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 35 $284,882
Invega Trinza Paliperidone Palmitate Brand 20 $199,216
Vraylar Cariprazine Hcl Brand 116 $162,145
Invega Sustenna Paliperidone Palmitate Brand 45 $138,248
Wellbutrin Xl Bupropion Hcl Brand 24 $52,886
Rexulti Brexpiprazole Brand 26 $51,651
Risperdal Consta Risperidone Microspheres Brand 12 $31,440
Lybalvi Olanzapine/Samidorphan Malate Brand 14 $22,250
Neurontin Gabapentin Brand 12 $19,496
Savella Milnacipran Hcl Brand 22 $12,234

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$5,354

Medicare's payments for the services billed

Medicare patients

50

Average age 61

Services billed

100

33 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Depression 46%
Diabetes 44%
Arthritis 40%
Ischemic heart disease 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $108
$108 35 —
CAPLYTA
  • ITI, Inc. $72
$72 — —
VRAYLAR
  • AbbVie, Inc. $71
$71 116 —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $51
$51 — —
ARISTADA
  • Alkermes, Inc. $46
$46 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

217 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record